Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy of CRx-102 in Subjects With Symptomatic Knee Osteoarthritis and Optional One-Year Extension

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dipyridamole/prednisolone (Primary) ; Prednisolone
  • Indications Osteoarthritis
  • Focus Therapeutic Use
  • Acronyms COMET-1
  • Sponsors Zalicus

Most Recent Events

  • 28 Apr 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
  • 22 Oct 2009 Results of the 12-month extension were announced at the American College of Rheumatology (ACR) 2009 Annual Meeting, according to CombinatoRx media release.
  • 13 Jun 2009 Resultswere reported at the 2009 EURLAR.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top